Mutations in the zinc finger domain of IKKγ block the activation of NF-κB and the induction of IL-2 in stimulated T lymphocytes

Molecular Immunology

Volumn 45, Issue 6, 2008, Pages 1633-1645

  Shifera, Amde Selassie ^a   Horwitz, Marshall S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cell activation; Cytokines; Immunodeficiency diseases; T cell receptors; T Cells

Indexed keywords

I KAPPA B ALPHA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; IONOMYCIN;

ARTICLE; CELL ACTIVATION; CELL LINE; CELL MUTANT; DNA BINDING; GENE EXPRESSION; HEAVY CHAIN; HYPOHIDROTIC ECTODERMAL DYSPLASIA; IMMUNE DEFICIENCY; MOUSE; MUTATION; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN INDUCTION; REPORTER GENE; STIMULATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; WILD TYPE; ZINC FINGER MOTIF;

ENZYME INDUCTION; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INTERLEUKIN-2; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MUTATION; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; PHOSPHORYLATION; T-LYMPHOCYTES; TRANSCRIPTION FACTOR AP-1; ZINC FINGERS;

EID: 39149094918     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.09.036     Document Type: Article

References (66)

1. Aradhya S., Courtois G., Rajkovic A., Lewis R.A., Levy M., Israel A., and Nelson D.L. Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma). Am. J. Hum. Genet. 68 (2001) 765-771
2. Aradhya S., Woffendin H., Jakins T., Bardaro T., Esposito T., Smahi A., Shaw C., Levy M., Munnich A., D'Urso M., Lewis R.A., Kenwrick S., and Nelson D.L. A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations. Hum. Mol. Genet. 10 (2001) 2171-2179
3. Bandyopadhyay S., Dure M., Paroder M., Soto-Nieves N., Puga I., and Macian F. Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells. Blood 109 (2007) 2878-2886
4. Bloom J., and Pagano M. Experimental tests to definitively determine ubiquitylation of a substrate. Methods Enzymol. 399 (2005) 249-266
5. Bookout A.L., Cummins C.L., Mangelsdorf D.J., Pesola J.M., and Kramer M.F. High-throughput real-time quantitative reverse transcription PCR. In: Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., and Struhl K. (Eds). Current Protocols in Molecular Biology (2006), John Wiley & Sons, Hoboken, NJ 15.8.1-15.8.28
6. Brockman J.A., Scherer D.C., McKinsey T.A., Hall S.M., Qi X., Lee W.Y., and Ballard D.W. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol. Cell Biol. 15 (1995) 2809-2818
7. Chin Y.R., and Horwitz M.S. Mechanism for removal of tumor necrosis factor receptor 1 from the cell surface by the adenovirus RIDalpha/beta complex. J. Virol. 79 (2005) 13606-13617
8. Cohen L., Henzel W.J., and Baeuerle P.A. IKAP is a scaffold protein of the IkappaB kinase complex. Nature 395 (1998) 292-296
9. Daoussis D., Andonopoulos A.P., and Liossis S.N. Targeting CD40L: a promising therapeutic approach. Clin. Diagn. Lab Immunol. 11 (2004) 635-641
10. DiDonato J., Mercurio F., Rosette C., Wu-Li J., Suyang H., Ghosh S., and Karin M. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell Biol. 16 (1996) 1295-1304
11. Doffinger R., Smahi A., Bessia C., Geissmann F., Feinberg J., Durandy A., Bodemer C., Kenwrick S., Dupuis-Girod S., Blanche S., Wood P., Rabia S.H., Headon D.J., Overbeek P.A., Le D.F., Holland S.M., Belani K., Kumararatne D.S., Fischer A., Shapiro R., Conley M.E., Reimund E., Kalhoff H., Abinun M., Munnich A., Israel A., Courtois G., and Casanova J.L. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat. Genet. 27 (2001) 277-285
12. Etzioni A., and Ochs H.D. The hyper IgM syndrome-an evolving story. Pediatr. Res. 56 (2004) 519-525
13. Fujioka S., Niu J., Schmidt C., Sclabas G.M., Peng B., Uwagawa T., Li Z., Evans D.B., Abbruzzese J.L., and Chiao P.J. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol. Cell Biol. 24 (2004) 7806-7819
14. Fuleihan R.L. The hyper IgM syndrome. Curr. Allergy Asthma Rep. 1 (2001) 445-450
15. Gaffen S.L., and Liu K.D. Overview of interleukin-2 function, production and clinical applications. Cytokine 28 (2004) 109-123
16. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 (2002) 373-428
17. Harhaj E.W., Good L., Xiao G., Uhlik M., Cvijic M.E., Rivera-Walsh I., and Sun S.C. Somatic mutagenesis studies of NF-kappa B signaling in human T cells: evidence for an essential role of IKK gamma in NF-kappa B activation by T-cell costimulatory signals and HTLV-I Tax protein. Oncogene 19 (2000) 1448-1456
18. He K.L., and Ting A.T. Essential role for IKKgamma/NEMO in TCR-induced IL-2 expression in Jurkat T cells. Eur. J. Immunol. 33 (2003) 1917-1924
19. Heckford S.E., Gelmann E.P., Agnor C.L., Jacobson S., Zinn S., and Matis L.A. Distinct signals are required for proliferation and lymphokine gene expression in murine T cell clones. J. Immunol. 137 (1986) 3652-3663
20. Henn I.H., Bouman L., Schlehe J.S., Schlierf A., Schramm J.E., Wegener E., Nakaso K., Culmsee C., Berninger B., Krappmann D., Tatzelt J., and Winklhofer K.F. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci. 27 (2007) 1868-1878
21. Hu X. Proteolytic signaling by TNFalpha: caspase activation and IkappaB degradation. Cytokine 21 (2003) 286-294
22. Huang T.T., Feinberg S.L., Suryanarayanan S., and Miyamoto S. The zinc finger domain of NEMO is selectively required for NF-kappa B activation by UV radiation and topoisomerase inhibitors. Mol. Cell Biol. 22 (2002) 5813-5825
23. Huang Y., and Wange R.L. T cell receptor signaling: beyond complex complexes. J. Biol. Chem. 279 (2004) 28827-28830
24. Imbert V., Rupec R.A., Livolsi A., Pahl H.L., Traenckner E.B., Mueller-Dieckmann C., Farahifar D., Rossi B., Auberger P., Baeuerle P.A., and Peyron J.F. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 86 (1996) 787-798
25. Jain A., Ma C.A., Liu S., Brown M., Cohen J., and Strober W. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat. Immunol. 2 (2001) 223-228
26. Jin D.Y., and Jeang K.T. Isolation of full-length cDNA and chromosomal localization of human NF-kappaB modulator NEMO to Xq28. J. Biomed. Sci. 6 (1999) 115-120
27. Kawadler H., and Yang X. Lys63-linked polyubiquitin chains: linking more than just ubiquitin. Cancer Biol. Ther. 5 (2006) 1273-1274
28. Kovalenko A., Chable-Bessia C., Cantarella G., Israel A., Wallach D., and Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424 (2003) 801-805
29. Krappmann D., Hatada E.N., Tegethoff S., Li J., Klippel A., Giese K., Baeuerle P.A., and Scheidereit C. The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component. J. Biol. Chem. 275 (2000) 29779-29787
30. Krappmann D., Wulczyn F.G., and Scheidereit C. Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo. EMBO J. 15 (1996) 6716-6726
31. Kruppa G., Thoma B., Machleidt T., Wiegmann K., and Kronke M. Inhibition of tumor necrosis factor (TNF)-mediated NF-kappa B activation by selective blockade of the human 55-kDa TNF receptor. J. Immunol. 148 (1992) 3152-3157
32. Le B.O., Schmidt-Ullrich R., and Israel A. Promoter analysis of the gene encoding the I kappa B-alpha/MAD3 inhibitor of NF-kappa B: positive regulation by members of the rel/NF-kappa B family. EMBO J. 12 (1993) 5043-5049
33. Leonardi A., Chariot A., Claudio E., Cunningham K., and Siebenlist U. CIKS, a connection to Ikappa B kinase and stress-activated protein kinase. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 10494-10499
34. Li X., and Stark G.R. NFkappaB-dependent signaling pathways. Exp. Hematol. 30 (2002) 285-296
35. Li Y., Kang J., Friedman J., Tarassishin L., Ye J., Kovalenko A., Wallach D., and Horwitz M.S. Identification of a cell protein (FIP-3) as a modulator of NF-kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 1042-1047
36. Liu L., Kwak Y.T., Bex F., Garcia-Martinez L.F., Li X.H., Meek K., Lane W.S., and Gaynor R.B. DNA-dependent protein kinase phosphorylation of IkappaB alpha and IkappaB beta regulates NF-kappaB DNA binding properties. Mol. Cell Biol. 18 (1998) 4221-4234
37. Makris C., Roberts J.L., and Karin M. The carboxyl-terminal region of IkappaB kinase gamma (IKKgamma) is required for full IKK activation. Mol. Cell Biol. 22 (2002) 6573-6581
38. Martinez-Pomar N., Munoz-Saa I., Heine-Suner D., Martin A., Smahi A., and Matamoros N. A new mutation in exon 7 of NEMO gene: late skewed X-chromosome inactivation in an incontinentia pigmenti female patient with immunodeficiency. Hum. Genet. 118 (2005) 458-465
39. Neish A.S., Gewirtz A.T., Zeng H., Young A.N., Hobert M.E., Karmali V., Rao A.S., and Madara J.L. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 289 (2000) 1560-1563
40. Nishikomori R., Akutagawa H., Maruyama K., Nakata-Hizume M., Ohmori K., Mizuno K., Yachie A., Yasumi T., Kusunoki T., Heike T., and Nakahata T. X-linked ectodermal dysplasia and immunodeficiency caused by reversion mosaicism of NEMO reveals a critical role for NEMO in human T-cell development and/or survival. Blood 103 (2004) 4565-4572
41. Orange J.S., Brodeur S.R., Jain A., Bonilla F.A., Schneider L.C., Kretschmer R., Nurko S., Rasmussen W.L., Kohler J.R., Gellis S.E., Ferguson B.M., Strominger J.L., Zonana J., Ramesh N., Ballas Z.K., and Geha R.S. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J. Clin. Invest. 109 (2002) 1501-1509
42. Orange J.S., Jain A., Ballas Z.K., Schneider L.C., Geha R.S., and Bonilla F.A. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J. Allergy Clin. Immunol. 113 (2004) 725-733
43. Perkins N.D. Achieving transcriptional specificity with NF-kappa B. Int. J. Biochem. Cell Biol. 29 (1997) 1433-1448
44. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 8 (2007) 49-62
45. Rathore N., Matta H., and Chaudhary P.M. An evolutionary conserved pathway of nuclear factor-kappaB activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of IkappaBalpha. J. Biol. Chem. 279 (2004) 39358-39365
46. Rothwarf D.M., and Karin M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci. STKE 1999 (1999) RE1
47. Rothwarf D.M., Zandi E., Natoli G., and Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 395 (1998) 297-300
48. Rudolph D., Yeh W.C., Wakeham A., Rudolph B., Nallainathan D., Potter J., Elia A.J., and Mak T.W. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev. 14 (2000) 854-862
49. Rushworth S.A., Bravery C.A., and Thompson S. Human CD154 induces activation of porcine endothelial cells and up-regulation of MHC class II expression. Transplantation 72 (2001) 127-132
50. Schmid J.M., Junge S.A., Hossle J.P., Schneider E.M., Roosnek E., Seger R.A., and Gungor T. Transient hemophagocytosis with deficient cellular cytotoxicity, monoclonal immunoglobulin M gammopathy, increased T-cell numbers, and hypomorphic NEMO mutation. Pediatrics 117 (2006) e1049-e1056
51. Schmidt-Supprian M., Courtois G., Tian J., Coyle A.J., Israel A., Rajewsky K., and Pasparakis M. Mature T cells depend on signaling through the IKK complex. Immunity 19 (2003) 377-389
52. Schneider L.C. X-linked hyper IgM syndrome. Clin. Rev. Allergy Immunol. 19 (2000) 205-215
53. Schonbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol. Life Sci. 58 (2001) 4-43
54. Skov S., Bonyhadi M., Odum N., and Ledbetter J.A. IL-2 and IL-15 regulate CD154 expression on activated CD4 T cells. J. Immunol. 164 (2000) 3500-3505
55. Spencer E., Jiang J., and Chen Z.J. Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev. 13 (1999) 284-294
56. Stilo R., Liguoro D., Di J.B., Formisano S., Consiglio E., Leonardi A., and Vito P. Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator. J. Biol. Chem. 279 (2004) 34323-34331
57. Taggart C.C., Greene C.M., McElvaney N.G., and O'Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J. Biol. Chem. 277 (2002) 33648-33653
58. Tang E.D., Wang C.Y., Xiong Y., and Guan K.L. A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha. J. Biol. Chem. 278 (2003) 37297-37305
59. Temmerman S.T., Ma C.A., Borges L., Kubin M., Liu S., Derry J.M., and Jain A. Impaired dendritic-cell function in ectodermal dysplasia with immune deficiency is linked to defective NEMO ubiquitination. Blood 108 (2006) 2324-2331
60. Ting A.T., Pimentel-Muinos F.X., and Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J. 15 (1996) 6189-6196
61. Uehara T., Matsuno J., Kaneko M., Nishiya T., Fujimuro M., Yokosawa H., and Nomura Y. Transient nuclear factor kappaB (NF-kappaB) activation stimulated by interleukin-1beta may be partly dependent on proteasome activity, but not phosphorylation and ubiquitination of the IkappaBalpha molecule, in C6 glioma cells. Regulation of NF-kappaB linked to chemokine production. J. Biol. Chem. 274 (1999) 15875-15882
62. Ullman K.S., Northrop J.P., Verweij C.L., and Crabtree G.R. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu. Rev. Immunol. 8 (1990) 421-452
63. Wisdom R. AP-1: one switch for many signals. Exp. Cell Res. 253 (1999) 180-185
64. Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F., Kirk H.E., Kay R.J., and Israel A. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 93 (1998) 1231-1240
65. Yang F., Yamashita J., Tang E., Wang H.L., Guan K., and Wang C.Y. The zinc finger mutation C417R of I-kappa B kinase gamma impairs lipopolysaccharide- and TNF-mediated NF-kappa B activation through inhibiting phosphorylation of the I-kappa B kinase beta activation loop. J. Immunol. 172 (2004) 2446-2452
66. Zonana J., Elder M.E., Schneider L.C., Orlow S.J., Moss C., Golabi M., Shapira S.K., Farndon P.A., Wara D.W., Emmal S.A., and Ferguson B.M. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am. J. Hum. Genet. 67 (2000) 1555-1562